Skip to main content

Anthony Richard Rutter, PhD

Chief Scientific Officer at NRG Therapeutics Ltd

Location: Cambridge United Kingdom

Richard studied and trained in molecular neuroscience at Oxford and University of London in the UK before joining the Merck Sharp and Dohme Neuroscience Research Centre in 2000. Richard joined GSK in 2006 and relocated to Singapore where he established the GSK Singapore R&D Centre pharmacology laboratory. He later became department head overseeing the initiation of new projects to build a discovery pipeline as well as leading in vitro and in vivo biology to support a portfolio of preclinical drug discovery programs focusing on neurodegenerative disorders e.g., motor neuron disease and Huntington’s disease.

More recently Richard was CSO at Auspherix Ltd, a company that was developing a novel class of antibiotic. In 2018, Richard co-founded NRG Therapeutics Ltd which is developing novel inhibitors of the mitochondrial permeability transition pore for the treatment of Parkinson’s disease.

Associated Grants

  • Validation of a Novel Mitochondrial Drug Target for Parkinson’s Disease


  • Novel Inhibitors of Cell Death for the Treatment of People with Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.